ArticleBiotechnology for biofuels and bioproducts2026
Metabolic engineering strategies for sustainable de novo isobutylamine production by Corynebacterium glutamicum.
Article in Biotechnology for biofuels and bioproducts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShort-chain primary amines are a versatile group of molecules in biological systems, derived from the decarboxylation of amino acids or the transamination of carbonyl-containing molecules. Isobutylamine, the decarboxylation product of L-valine, has applications in chemical synthesis of pharmaceuticals, herbicides, fungicides and specialized chemicals, where it is especially interesting as a substitute for petrochemical compounds. Since the chemical synthesis of short-chain primary amines is hazardous and environmentally unsustainable, we established an efficient biosynthetic approach in this work.
resultsThe natural amino acid producer Corynebacterium glutamicum is an ideal chassis for the production of amino acid-derived molecules. In this study, we assessed the toxicity of several relevant short-chain primary amines on C. glutamicum. A crude extract assay demonstrated the decarboxylation of L-valine to isobutylamine by the L-valine decarboxylase VlmD
conclusionsThis study demonstrated the highest production of isobutylamine and the highest production of any microbial short-chain primary amine in minimal medium. In shake flask cultivation, an isobutylamine titer of 12.1 g/L and a yield of 0.74 mol isobutylamine/mol glucose were obtained. Transfer to a 3 L fed-batch bioreactor fermentation was successful and a titer of 33.2 g/L was reached within 64 h with a yield of 0.47 mol/mol and a volumetric productivity of 0.52 g/l/h. Moreover, isobutylamine production on a second-generation feedstock was shown, highlighting the potential of sustainable bio-based production of isobutylamine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.